

S3 Table. Inter-reader agreement of final categorization and imaging features of KLCA-NCC 2022 criteria on ECA-MRI and HBA-MRI

	ECA-MRI	HBA-MRI
	κ (95% CI)	κ (95% CI)
Final categorization according to KLCA-NCC 2022	0.82 (0.73-0.90)	0.83 (0.73-0.92)
Radiologic hallmarks of HCC		
Arterial phase hyperenhancement	0.78 (0.65-0.90)	0.74 (0.61-0.87)
Washout appearance ^{a)}	0.86 (0.76-0.95)	0.96 (0.89-1.00)
Ancillary imaging features		
Suggesting malignancy in general (group A)		
Mild-to-moderate T2 hyperintensity	0.89 (0.74-1.00)	0.89 (0.74-1.00)
High signal intensity on DWI	0.97 (0.92-1.00)	0.97 (0.92-1.00)
Threshold growth ^{b)}	-	-
Favoring HCC in particular (group B)		
Enhancing or non-enhancing capsule	0.82 (0.70-0.94)	0.74 (0.61-0.86)
Mosaic architecture	0.91 (0.81-1.00)	0.91 (0.81-1.00)
Nodule-in-nodule appearance	0.66 (0.04-1.00)	0.66 (0.04-1.00)
Fat in mass or blood products in mass	0.69 (0.51-0.87)	0.69 (0.51-0.87)
Marked T2 hyperintensity	0.89 (0.74-1.00)	0.89 (0.74-1.00)
Targetoid features		
Targetoid appearance on DWI	0.43 (0.09-0.78)	0.43 (0.09-0.78)
Targetoid appearance on contrast-enhanced images	0.88 (0.75-1.00)	0.83 (0.66-0.99)

DWI, diffusion-weighted image; ECA, extracellular agent; HBA, hepatobiliary agent; HCC, hepatocellular carcinoma; KLCA-NCC, Korean Liver Cancer Association-National Cancer Center. ^{a)}Washout appearance in the portal venous, delayed, or hepatobiliary phases, ^{b)}Threshold growth was not evaluated in our study due to the lack of available prior CT or MR examinations for comparison.